Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.3K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.3K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.3K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.7K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.7K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.3K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.3K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

628
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
628

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A note on rank-preserving structural failure time models to account for crossover.

Clinical trials (London, England)·2026
Same author

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

SLAS discovery : advancing life sciences R & D·2025
Same author

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.

Clinical trials (London, England)·2025
Same author

Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.

JCO oncology advances·2025
Same journal

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same journal

Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

Journal of the National Cancer Institute·2026
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
Same journal

Welcome reduction of US cervical cancer rates despite state differences.

Journal of the National Cancer Institute·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Dose optimization during drug development: whether and when to optimize.

Edward L Korn1, Jeffrey A Moscow2, Boris Freidlin1

  • 1Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.

Journal of the National Cancer Institute
|December 19, 2022
PubMed
Summary
This summary is machine-generated.

Optimizing drug dosage aims for efficacy and safety. Delaying formal dose optimization until after clinical activity is established prevents exposing patients to ineffective therapies, serving public health interests.

More Related Videos

Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Related Experiment Videos

Last Updated: Aug 16, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Area of Science:

  • Pharmacology
  • Drug Development
  • Clinical Trials

Background:

  • Dose optimization seeks to balance clinical benefit and tolerability.
  • Traditionally, maximum tolerated dose from Phase I informs Phase II trials, with limited formal optimization in later stages.
  • Recent suggestions propose early, formal dose optimization before confirming therapeutic activity.

Purpose of the Study:

  • To evaluate the advantages of early versus late dose optimization in drug development.
  • To determine the optimal timing for formal dose optimization to maximize patient benefit and minimize exposure to ineffective treatments.

Main Methods:

  • Comparative analysis of early versus late dose optimization strategies.
  • Modeling patient exposure to therapies based on optimization timing.

Main Results:

  • Performing dose optimization early risks exposing a significant number of patients to ineffective drugs.
  • Delaying dose optimization until after clinical activity is demonstrated is more efficient.

Conclusions:

  • Formal dose optimization should ideally be conducted after or during Phase III trials.
  • Exceptions include cases where Phase II trials show clear clinical activity, suggesting optimization post-Phase II.